Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ursobil versus silymarin in fatty liver disease
IRCT2016040727265N1Phase 3Completed
- Sponsor
- Qazvin University of Medical Sciences
- Start
- Aug 2015
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Small Molecules
- Countries
- 1
01
Overview
Phase 3, open-label trial of ursodeoxycholic acid and silymarin in metabolic dysfunction-associated steatohepatitis (MASH) and metabolic dysfunction-associated steatotic liver disease (MASLD) (2 arms), sponsored by Qazvin University of Medical Sciences. Started Aug 2015; status: completed.
02
Drugs
ursodeoxycholic acidsilymarin
03
Conditions
metabolic dysfunction-associated steatohepatitis (MASH)metabolic dysfunction-associated steatotic liver disease (MASLD)
Beyond the preview
Go deeper on IRCT2016040727265N1.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on IRCT2016040727265N1.